Company announcement no 3/2023 - Annual Account / Report Q4 2022
Annual Account / Report Q4 2022
EBITDA fixed herd prices (FHP) for Q4 2022 increased to 5.746 mEUR (Q4 2021: -1.039 kEUR), corresponding to an EBITDA margin FHP of
15.2% (Q4 2021: -5.1%). The quarterly EBITDA in Q4 2022 increased by 6.332 kEUR (compared to Q4 2021). Mainly driven by improved sales prices, as they in Q4 2022 were 1.56 EUR/kg live weight, up from 1.00 EUR/kg Q4 2021.
Feed prices in Q4 2022 were 356 EUR/T (compared to 294 EUR/T Q1-Q3 2022). End December 2022 4.8 mEUR hedging gains are included in Group equity in other reserves, which will be released into EBITDA during next 9 months.
The herd valuation in Q4 increased by 2,840 kEUR (compared to 30.09.2022). The increase is driven by increasing price in EU, as the market is moving towards balance of demand/supply of pork. FY2022 the herd prices are have increased significant, driven by increasing prices, total increase is 8.430 kEUR predominate in Lithuania.
Net interest-bearing debt (NIBD) decreased to EUR 66.5m in 2022, being EUR 12.0m lower than in 2021 (78.5 mEUR). Nevertheless, the following need to be considered EUR 4,8 from hedging transactions which will be included in EBITDA in 2023. Idavang has almost three years duration with the EUR 75m bond left, hence having very stable financing.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast27.3.2023 15:05:00 CEST | Press release
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference C
Transactions in connection with share buy-back program27.3.2023 15:00:41 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 27, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares. The following transactions were executed under the program from March 20, 2023, to March 24, 2023: No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement167,000427,631,620March 20, 20236,0002,504.2415,025,440March 21, 20235,000 2,541.7712,708,850March 22,20235,0002,541.4412,707,200March 23, 20237,0002,529.9917,709,930March 24, 20237,0002,564.9117,954,370Total30,00076,105,790Accumulated under the program197,000503,737,410 Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 740,416 shares as treasury shares, corresponding to 1.12% of the to
Philips Virtual Care Management offers a comprehensive approach to telehealth for patients, providers and payers27.3.2023 15:00:00 CEST | Press release
March 27, 2023 New solution demonstrates proven results in improving patient engagement, health outcomes, and lowering cost of care while enabling workflow efficiencies Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the debut of Philips Virtual Care Management, a comprehensive portfolio of flexible solutions and services to help health systems, providers, payers and employer groups more meaningfully motivate and deeply connect with patients from virtually anywhere. Philips Virtual Care Management can help reduce pressure on hospital staff by decreasing emergency department visits, as well as reducing the cost of care through better management of chronic disease . Every year, chronic condition management represents 90% of healthcare expenditures in the USA . Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, heart disease, chronic kidney disease, chronic obst
Changes to the Yara Group Executive Board27.3.2023 15:00:00 CEST | Press release
Oslo, 27 March 2023: Pål Hestad, EVP Global Plants & Operational Excellence, has asked to step down from his current position for personal reasons, and will take on a different role in Yara. “Pål has safely led the Global Plants & Operational Excellence organization through an extraordinary period dominated by a pandemic and war which resulted in a demanding situation for a global operation like ours. Pål has now asked to step down and will continue to work for Yara in a different role. I would like to thank him for his contribution to the Group Executive Board over the past close to three years,” says Svein Tore Holsether, President & CEO. Pål will continue in the role until his replacement has been found. Contact Maria Gabrielsen, Investor Relations Mobile phone: +47 92090093 Email: email@example.com Tonje Næss, Media Relations Mobile phone: +47 40844647 Email: firstname.lastname@example.org About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting
Innovative Producer, Filmmaker and Author Mick Ebeling to Join Duck Creek’s Formation ’23 as Keynote Speaker27.3.2023 14:30:00 CEST | Press release
Ebeling will discuss pushing the bar and making the inconceivable, the unbelievable and the impossible, not impossible Boston, March 27, 2023 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, welcomes Mick Ebeling as its Formation ’23 keynote speaker. Formation, Duck Creek’s annual user conference, attracts the world’s leading insurance industry and technology minds and takes place in Orlando, FL, May 8-10, 2023. Ebeling is the founder and CEO of Not Impossible, a critically acclaimed, award-winning social lab and production company that taps into the power of technology and story to change the world. Formation '23 will empower the P&C and general insurance community with the insights, technology, and inspiration to build better human experiences. As the industry comes together to collaborate and reimage the future of P&C technology, the conference’s theme, “building together,” is me